Open AccessClinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China
Author(s) -
Jianjun Sun,
Li Liu,
Jiangrong Wang,
Yinzhong Shen,
Tangkai Qi,
Zhenyan Wang,
Yang Tang,
Wei Song,
Jun Chen,
Ren-Fang Zhang
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001180
Subject(s) - medicine , vincristine , international prognostic index , diffuse large b cell lymphoma , rituximab , epoch (astronomy) , chop , prednisone , interquartile range , lymphoma , oncology , cyclophosphamide , chemotherapy , stars , physics , astronomy
Numerous studies have focused on lymphoma among patients infected with human immunodeficiency virus (HIV). However, little is known about the treatment options and survival rate of lymphoma in the Chinese people living with HIV (PLHIV). Our study aimed to investigate the prognosis and compare outcome of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab(R-CHOP) as front line therapy for PLHIV with diffuse large B-cell lymphoma (DLBCL) receiving modern combined antiretroviral therapy (cART).